Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, MN.
The Heart Hospital Baylor, Plano, TX.
Prog Cardiovasc Dis. 2014 May-Jun;56(6):610-8. doi: 10.1016/j.pcad.2014.03.001. Epub 2014 Mar 5.
Transcatheter aortic valve replacement (TAVR) is a transformative technology for the treatment of aortic stenosis, requiring a multidisciplinary collaboration in the form of a "heart team" that includes interventional cardiologists and cardiac surgeons. As this new technology continues to disperse rapidly, its proper therapeutic role evolves and leads to important questions regarding who should perform the procedure, where it should be performed, and who should pay for it. Herein, we review the most recent guidelines governing the use of TAVR in the United States and Europe. We then summarize the available registry data, which, despite its limitations, presents the clearest picture of TAVR in clinical use. Finally, we discuss the costs and relative cost-effectiveness of TAVR. Taken together, these are the elements from which the larger questions surrounding TAVR must be answered.
经导管主动脉瓣置换术(TAVR)是一种治疗主动脉瓣狭窄的变革性技术,需要以“心脏团队”的形式进行多学科合作,其中包括介入心脏病专家和心脏外科医生。随着这项新技术的迅速普及,其治疗作用也在不断发展,并引发了一些重要问题,例如谁来进行该手术、在哪里进行以及谁来支付费用。本文回顾了指导美国和欧洲 TAVR 使用的最新指南。然后,我们总结了现有的登记数据,这些数据虽然存在局限性,但最清晰地展示了 TAVR 在临床应用中的情况。最后,我们讨论了 TAVR 的成本和相对成本效益。综上所述,这些都是必须回答的关于 TAVR 的更大问题的要素。